Michael Yee

Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments

Why This Moderna Analyst Is Turning Bullish On Drugmaker's Pipeline

Why Shares Of COVID-19 Vaccine Maker Moderna Are Shooting Higher On Monday

Why This Moderna Analyst Is Turning Bullish On Drugmaker's Pipeline

Why Shares Of COVID-19 Vaccine Maker Moderna Are Shooting Higher On Monday

Why Moderna Stock Is Trading Higher Today

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'

Why Moderna Stock Is Trading Higher Today

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'

Moderna Analyst: Phase 3 Coronavirus Data Could Arrive As Soon As October

Moderna Analyst: Coronavirus Vaccine Will Get Approved, Clock $5B+ In Orders Over Next Few Years

Michael Yee Recent News

Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill

Jefferies On Gilead: 'We See Better Days Ahead'

3 Highlights From A Spark Therapeutics Fireside Chat

RBC Hints At Potential M&A For Kite Pharma

There's A Historical Precedent For The Biotech Selloff

M&A In Small-, Mid-Cap Biotechs Isn't Slowing Down

Is More M&A On The Way For Large-Cap Biotechs?

RBC's Michael Yee Still Sees Value in Biogen's Long-Term Pipeline

Biogen's Parkinson's Antibody Could Boost Prothena, RBC Says

Large-Cap Biotechs Poised For Second-Half Rally, RBC Says

Top Street Analysts Like Gilead Sciences

Can Gilead Really Post EPS Growth Above 50%?

What's Wall Street Been Saying About Gilead Lately?

Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says

Will Intercept Pharma Outperform? These Analysts Think So

XenoPort Soars 9% Following Comments From RBC's Michael Yee

Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More

RBC Sees Weak Merck Data As Positive For Gilead

Why Investors Should Closely Watch Celgene

Tekmira Sinks 15%; Anti-Ebola Drug Trial Halted For Safety Concerns